登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>B7-1 >B71-H5228

Human B7-1 / CD80 Protein, His Tag (MALS verified)

分子别名(Synonym)

CD80,B7,B7-1,B7.1,BB1,CD28LG,CD28LG1,LAB7

表达区间及表达系统(Source)

Human B7-1, His Tag (B71-H5228) is expressed from human 293 cells (HEK293). It contains AA Val 35 - Asn 242 (Accession # P33681-1 ).

Predicted N-terminus: Val 35

Request for sequence

蛋白结构(Molecular Characterization)

B7-1 Structure

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 25.8 kDa. The protein migrates as 40-60 kDa under reducing (R) condition (SDS-PAGE) due to different glycosylation.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

B7-1 SDS-PAGE

Human B7-1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

SEC-MALS

B7-1 SEC-MALS

The purity of Human B7-1, His Tag (Cat. No. B71-H5228) is more than 90% and the molecular weight of this protein is around 35-45 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

B7-1 ELISA

Immobilized Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) at 10 μg/mL (100 μL/well) can bind Human B7-1, His Tag (Cat. No. B71-H5228) with a linear range of 0.078-1.25 μg/mL (QC tested).

Protocol

B7-1 BATCH ELISA
 

活性(Bioactivity)-SPR

B7-1 SPR

Immobilized Human / Cynomolgus / Rhesus macaque CD28, Fc Tag (Cat. No. CD8-H525a) on CM5 Chip can bind Human B7-1, His Tag (Cat. No. B71-H5228) with an affinity constant of 5.29 μM as determined in a SPR assay (Biacore T200) (Routinely tested).

Protocol

 

活性(Bioactivity)-BLI

B7-1 BLI

Loaded Human PD-L1, Fc Tag (Cat. No. PD1-H5258) on Protein A Biosensor, can bind Human B7-1, His Tag (Cat. No. B71-H5228) with an affinity constant of 18 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

B7-1 BLI

Loaded Human / Cynomolgus / Rhesus macaque CD28, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. CD8-H52A5) on Protein A Biosensor, can bind Human B7-1, His Tag (Cat. No. B71-H5228) with an affinity constant of 2.1 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

B7-1 BLI

Loaded Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) on Protein A Biosensor, can bind Human B7-1, His Tag (Cat. No. B71-H5228) with an affinity constant of 0.52 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

 

背景(Background)

B7-1 and B7-2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response.
B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

 

前沿进展

 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
B7-1靶点信息
英文全称:Cluster of differentiation 80
中文全称:分化群80
种类:Homo sapiens
上市药物数量:2详情
临床药物数量:6详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定